RJA
DXCM icon

Ross\Johnson & Associates’s DexCom DXCM Stock Holding History

Ross\Johnson & Associates’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202 Hold
3
– – ﹤0.01% 227
2026
Q1 		$188 Hold
3
– – ﹤0.01% 172
2025
Q4 		$199 Hold
3
– – ﹤0.01% 246
2025
Q3 		$202 Hold
3
– – ﹤0.01% 171
2025
Q2 		$262 Hold
3
– – 0.01% 157
2025
Q1 		$204 Buy
+3
New +$245 ﹤0.01% 314

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Ross\Johnson & Associates's DXCM Position: Q2 2026 in Review

Ross\Johnson & Associates held its DexCom (DXCM) position steady in Q2 2026 at 3 shares worth $202. The position accounts for ﹤0.01% of the portfolio, ranked #227.

Ross\Johnson & Associates first reported a position in DXCM in Q1 2025 and has held it in 6 quarters since. The position peaked at $262 in Q2 2025. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Ross\Johnson & Associates held 3 shares of DexCom worth $202 as of Q2 2026.
  • Ross\Johnson & Associates left its DexCom share count unchanged in Q2 2026.
  • DexCom made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #227 holding.
  • Ross\Johnson & Associates first reported a position in DexCom in Q1 2025 and has held it in 6 quarters since.
  • Ross\Johnson & Associates's DexCom position peaked at $262 in Q2 2025.
  • 973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.